SillaJen raises $37M in venture round

SillaJen Inc. (Busan, South Korea) raised $37 million in a venture round, including $12 million from Medivate Partners. SillaJen VP of Product and Alliance Management Robin Scully told BioCentury that Hana Financial Investment also participated.

Medivate said SillaJen plans to conduct an IPO in Korea by YE16. It said the funding will support SillaJen's Phase III trial of oncolytic virus candidate Pexa-Vec pexastimogene devacirepvec ( JX-594) to treat liver cancer. Pexa-Vec is a recombinant vaccinia virus that expresses GM-CSF and lacks thymidine kinase. ...